Bakirtzis Christos, Nikolaidis Ioannis, Boziki Marina-Kleopatra, Grigoriadou Eleni, Karakasi Maria-Valeria, Moysiadis Theodoros, Kesidou Evangelia, Papazisis Georgios, Grigoriadis Nikolaos
From the Multiple Sclerosis Center, 2nd Department of Neurology (CB, IN, M-KB, EG, EK, NG), Aristotle University of Thessaloniki, Thessaloniki, Greece.
C' Department of Psychiatry (M-VK), Aristotle University of Thessaloniki, Thessaloniki, Greece.
Int J MS Care. 2023 Jul-Aug;25(4):140-144. doi: 10.7224/1537-2073.2022-046. Epub 2023 Jan 16.
Besides disease-modifying therapies, various pharmacologic agents are frequently prescribed to people with multiple sclerosis (MS) for symptom treatment and for comorbid conditions. The present study aims to investigate the types and frequencies of agents prescribed to people with MS in Greece using records from the nationwide digital prescription database.
Prescription records for 21,218 people (65.9% women) with MS were included in the study. The criterion for study inclusion was a minimum of 3 months of continuous prescription of an agent. Identified treatments were further examined by age group.
Antispasticity agents (17.5%) and fampridine (14.5%) were the most regularly prescribed symptomatic medications. Antihypertensives (21.1%) and drugs for affective disorders, including antidepressants (36.1%) and anxiolytics (16.2%), were the most frequently prescribed medications for comorbid conditions. Antidepressants were prescribed at almost equally high rates among individuals older than 40 years. Hypertension was one of the leading comorbidities among the study sample, with rates rising significantly after age 40 years and plateauing after age 60 years. Polypharmacy was observed in 22.5% of the study sample, with a higher incidence among people with MS older than 60 years (46.98%).
Agents prescribed for the treatment of disease symptoms and other medical conditions are expected to positively affect quality of life in people with MS. However, polypharmacy seems to be particularly high, especially in the aged population. The potential implications of polypharmacy in the disease course should further be explored.
除了疾病改善疗法外,多种药物制剂也经常被开给多发性硬化症(MS)患者用于症状治疗和合并症治疗。本研究旨在利用全国数字处方数据库中的记录,调查希腊MS患者所开药物的类型和频率。
本研究纳入了21218名MS患者的处方记录(女性占65.9%)。纳入研究的标准是至少连续3个月使用某种药物。确定的治疗方法按年龄组进一步检查。
抗痉挛药物(17.5%)和氨吡啶(14.5%)是最常开具的对症药物。抗高血压药物(21.1%)以及用于情感障碍的药物,包括抗抑郁药(36.1%)和抗焦虑药(16.2%),是合并症最常开具的药物。40岁以上个体中抗抑郁药的处方率几乎同样高。高血压是研究样本中的主要合并症之一,40岁后发病率显著上升,60岁后趋于平稳。22.5%的研究样本存在多药联用情况,60岁以上MS患者中多药联用的发生率更高(46.98%)。
用于治疗疾病症状和其他医疗状况的药物有望对MS患者的生活质量产生积极影响。然而,多药联用似乎尤其普遍,特别是在老年人群中。应进一步探讨多药联用在疾病进程中的潜在影响。